Best Peptides for Body Recomposition — Real Peptides

Best Peptides for Body Recomposition — Real Peptides

Body recomposition. The simultaneous reduction of fat mass and increase in lean muscle tissue. Is one of the hardest physiological outcomes to achieve through diet and training alone. Research from the University of Jyväskylä found that trained individuals in energy balance gain less than 0.5kg of lean mass while losing fat over 12 weeks, and most plateau entirely after six months. The limitation isn't effort. It's hormonal. Growth hormone secretion declines roughly 14% per decade after age 30, insulin sensitivity decreases with chronic dieting, and lipolytic enzymes downregulate under caloric restriction. Peptides that target these exact pathways. Growth hormone releasing peptides, insulin sensitizers, and metabolic modulators. Create the hormonal environment where simultaneous fat loss and muscle gain become mechanistically possible.

We've worked with researchers evaluating peptide protocols for body recomposition across hundreds of studies. The difference between peptides that produce measurable changes in body composition versus those that don't comes down to receptor specificity, dosing frequency, and stacking logic most online guides never mention.

What are the best peptides for body recomposition?

The best peptides for body recomposition include growth hormone secretagogues like CJC-1295/Ipamorelin, MK-677, and Tesamorelin, which elevate endogenous growth hormone and IGF-1 levels to promote lipolysis and protein synthesis. Metabolic modulators like AOD-9604 target fat oxidation without affecting insulin or glucose metabolism, while recovery peptides like BPC-157 and TB-500 support tissue repair during high-volume training required for recomposition.

The distinction matters because body recomposition isn't weight loss. It's a hormonal recalibration that allows the body to partition nutrients toward muscle protein synthesis while simultaneously activating hormone-sensitive lipase. The enzyme responsible for breaking down stored triglycerides. Standard caloric restriction suppresses both anabolic and lipolytic hormones, which is why simultaneous fat loss and muscle gain rarely happen in a deficit beyond the novice stage. Peptides interrupt that hormonal suppression.

This article covers which peptide classes produce measurable recomposition outcomes, the mechanisms that differentiate effective protocols from ineffective ones, and the stacking strategies that optimize receptor signaling without redundancy.

Growth Hormone Secretagogues That Drive Simultaneous Fat Loss and Lean Mass Gains

Growth hormone secretagogues (GHS) are the foundational category for body recomposition because they address the rate-limiting hormonal factor: declining growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. GH stimulates lipolysis by activating hormone-sensitive lipase in adipose tissue while simultaneously increasing IGF-1 production in the liver, which drives muscle protein synthesis through mTOR pathway activation. Without adequate GH and IGF-1, the body cannot efficiently mobilize fat stores and build lean tissue at the same time. It prioritizes one at the expense of the other.

CJC-1295 without DAC is a growth hormone releasing hormone (GHRH) analog that extends the half-life of endogenous GHRH from minutes to days, allowing sustained elevation of GH pulses without the flattening effect seen with continuous GHRH infusion. When combined with Ipamorelin. A selective ghrelin receptor agonist (growth hormone releasing peptide, or GHRP). The result is synergistic: GHRH analogs amplify the pulse, while GHRPs increase pulse frequency. A study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that GHRH/GHRP combinations produce 2–3× the GH release of either peptide alone, with IGF-1 levels elevated 20–30% above baseline at steady state.

The CJC-1295/Ipamorelin stack is the most widely studied protocol for recomposition. Typical dosing involves 200–300mcg of each peptide administered subcutaneously before bed to align with natural nocturnal GH pulses, though some protocols dose twice daily (morning fasted and pre-bed). The half-life difference matters: CJC-1295 without DAC maintains elevated GHRH for 6–8 days, while Ipamorelin clears within 2 hours. The short-acting GHRP triggers the pulse, and the long-acting GHRH sustains the amplitude.

MK-677 (Ibutamoren) is an orally bioavailable ghrelin mimetic that produces sustained GH and IGF-1 elevation without injections. Unlike peptide GHRPs, MK-677 has a half-life of 24 hours, meaning once-daily dosing at 15–25mg maintains elevated GH throughout the day. The trade-off is receptor specificity: MK-677 binds to ghrelin receptors in the hypothalamus and gut, which increases appetite in 60–70% of users. A significant consideration during recomposition when caloric control is critical. Clinical trials show MK-677 increases lean body mass by 1.1–2.7kg over 12 months in adults with age-related GH deficiency, with concurrent reductions in visceral fat.

Tesamorelin is a synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in patients with HIV-associated lipodystrophy. It produces predictable, dose-dependent GH release. 2mg daily subcutaneous injection increases IGF-1 by approximately 80–100ng/mL and reduces visceral fat by 15–18% over six months without affecting subcutaneous fat or glucose metabolism. This selectivity for visceral fat makes Tesamorelin particularly valuable for individuals with elevated waist circumference and metabolic dysfunction, where visceral adiposity drives insulin resistance. The Tesamorelin/Ipamorelin stack combines GHRH analog precision with GHRP pulse frequency for compounded effect.

Hexarelin is the most potent GHRP by GH output. 100mcg produces GH release comparable to 200mcg of GHRP-2 or GHRP-6. But long-term use causes desensitization of ghrelin receptors, reducing efficacy after 12–16 weeks. For this reason, Hexarelin is best used in short, high-intensity recomposition phases (8–12 weeks) rather than continuous protocols. It also increases prolactin and cortisol more than other GHRPs, which limits its appeal for extended use.

IGF-1 LR3 is a synthetic analog of IGF-1 with reduced binding affinity to IGF binding proteins, resulting in a half-life of 20–30 hours versus 12–15 hours for endogenous IGF-1. It acts directly on muscle and fat tissue without requiring GH intermediation, making it the only peptide in this category that bypasses the GH-IGF-1 axis entirely. Dosing is typically 40–80mcg daily post-workout, injected locally or systemically. IGF-1 LR3 is highly anabolic but also highly mitogenic. Long-term safety data is sparse, and its use is primarily limited to short recomposition cycles of 4–6 weeks.

The common mechanism across all growth hormone secretagogues is dual-action: lipolysis through GH's direct effect on adipose tissue, and anabolism through IGF-1's effect on skeletal muscle. The peptide you choose depends on whether appetite stimulation is tolerable (MK-677), whether visceral fat is the primary target (Tesamorelin), or whether pulsatile GH release mimicking natural physiology is the goal (CJC-1295/Ipamorelin).

Metabolic Modulators and Lipolytic Peptides That Accelerate Fat Oxidation Without Muscle Loss

While growth hormone secretagogues create the anabolic environment for recomposition, metabolic modulators specifically target fat oxidation pathways without affecting muscle protein synthesis or glucose metabolism. These peptides activate lipolytic enzymes, increase mitochondrial biogenesis, or modulate energy partitioning. Making them ideal for stacking with GH secretagogues when fat loss is the primary limiting factor.

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (amino acids 176–191) that retains GH's lipolytic effects without its growth-promoting or insulin-antagonistic properties. Preclinical studies show AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue by mimicking the way GH regulates fat metabolism. Importantly, it does not bind to GH receptors in muscle or liver, so it does not increase IGF-1, affect blood glucose, or promote tissue growth. Typical dosing is 250–500mcg subcutaneously once daily, ideally fasted or pre-exercise. Clinical trials in humans demonstrated modest fat loss (0.5–1.0kg over 12 weeks) without changes in lean mass, glucose, or insulin. Making AOD-9604 a pure fat-loss agent with minimal systemic effects.

The mechanism is localized: AOD-9604 upregulates beta-3 adrenergic receptors in white adipose tissue, increasing cAMP (cyclic adenosine monophosphate) and activating hormone-sensitive lipase. The same enzyme GH activates, but without the downstream effects on IGF-1 or glucose. This makes AOD-9604 particularly useful for individuals who want targeted fat oxidation without appetite suppression, insulin sensitivity changes, or anabolic signaling. It's mechanistically inert outside adipose tissue.

MOTS-c is a mitochondrial-derived peptide that regulates energy metabolism by improving insulin sensitivity and increasing glucose uptake in skeletal muscle. It activates AMPK (AMP-activated protein kinase), the cellular energy sensor that shifts metabolism from anabolic (storage) to catabolic (oxidation) states. AMPK activation increases fatty acid oxidation, inhibits lipogenesis, and promotes mitochondrial biogenesis. The creation of new mitochondria, which improves metabolic capacity. Research published in Cell Metabolism found that MOTS-c administration in mice prevented diet-induced obesity and insulin resistance, with marked improvements in glucose tolerance and reduction in visceral fat accumulation. Dosing in humans is typically 5–10mg subcutaneously 2–3 times per week. MOTS-c does not directly increase GH or IGF-1, so it complements growth hormone secretagogues by improving nutrient partitioning. Calories are preferentially oxidized rather than stored.

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that regulates NAD+ availability and cellular energy expenditure. NNMT overexpression is associated with obesity and metabolic dysfunction. Inhibiting it increases NAD+ levels, which activates sirtuins and AMPK, promoting fat oxidation and improving insulin sensitivity. Preclinical data shows 5-Amino-1MQ reduces body fat by 25–30% over 10 weeks in rodent models without changes in food intake, suggesting a metabolic rather than appetite-mediated effect. Typical human dosing is 50–100mg oral or subcutaneous daily. The mechanism is systemic metabolic reprogramming rather than direct lipolysis, making it a long-term metabolic optimizer rather than a short-term fat-loss agent.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed as an antidepressant but repurposed for obesity treatment after Phase II trials showed 10–12% body weight reduction over 24 weeks. Significantly greater than any FDA-approved obesity drug at the time. Tesofensine increases energy expenditure and reduces appetite through CNS stimulation, with norepinephrine being the primary driver of thermogenesis. Dosing is 0.25–0.5mg oral daily. The stimulant profile means side effects include elevated heart rate and blood pressure in some users, so cardiovascular health must be assessed before use. Tesofensine is not a peptide in structure (it's a small molecule), but it's frequently used in peptide recomposition protocols for its potent fat-loss effects.

Survodutide and Mazdutide are dual GLP-1/glucagon receptor agonists currently in Phase III trials for obesity and type 2 diabetes. The dual mechanism is powerful: GLP-1 receptor agonism slows gastric emptying and increases satiety (reducing caloric intake), while glucagon receptor agonism increases hepatic fat oxidation and energy expenditure. Clinical data for Survodutide shows 15–18% body weight reduction over 46 weeks with preserved lean mass. The glucagon component prevents the muscle loss typically seen with GLP-1 monotherapy. Dosing is once-weekly subcutaneous injection, titrated from 1.2mg to 4.8mg. These are not yet FDA-approved, but their dual-action makes them mechanistically ideal for recomposition. Appetite suppression without metabolic slowdown.

The distinction between lipolytic and metabolic peptides is timing and mechanism: AOD-9604 and Tesofensine produce acute fat oxidation, while MOTS-c and 5-Amino-1MQ reprogram energy metabolism over weeks to months. Stacking both types creates short-term fat loss and long-term metabolic adaptation.

Recovery and Anabolic Support Peptides That Sustain Training Volume During Recomposition

Body recomposition requires sustained high-volume resistance training to provide the stimulus for muscle protein synthesis while in a neutral or slight caloric deficit. The physiological challenge is recovery: training volume that drives hypertrophy also produces microtrauma, inflammation, and connective tissue stress. Without adequate recovery, training frequency drops, volume decreases, and the anabolic stimulus disappears. Fat loss may continue, but lean mass stagnates or declines. Recovery peptides don't directly burn fat or build muscle. They allow you to train hard enough, frequently enough, to produce the stimulus that GH secretagogues and metabolic modulators can act on.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective gastric protein. It accelerates healing of muscle, tendon, ligament, and bone tissue by upregulating growth factors including VEGF (vascular endothelial growth factor) and modulating the nitric oxide pathway. Preclinical studies show BPC-157 accelerates tendon-to-bone healing, reduces inflammation in muscle injuries, and improves blood flow to damaged tissue. Dosing is typically 250–500mcg subcutaneously once or twice daily, either systemically or near the injury site. For recomposition, BPC-157's value is systemic recovery. It reduces the cumulative inflammatory load from high-frequency training, allowing 5–6 training sessions per week without overuse injuries or chronic joint pain that would otherwise force deload weeks.

BPC-157 also demonstrates gastric protective effects, which matters during recomposition when caloric restriction and stimulant use (caffeine, Tesofensine) increase gastric acidity. It does not directly affect body composition, but it removes the recovery bottleneck that limits training volume.

TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that promotes cellular migration, angiogenesis (new blood vessel formation), and tissue repair. It's present in high concentrations in wound fluid and plays a role in downregulating inflammatory cytokines while upregulating actin. A structural protein critical for cell movement and tissue remodeling. TB-500 is systemically acting, meaning it doesn't require local injection. Typical dosing is 2–5mg subcutaneously twice weekly for the first 4–6 weeks (loading phase), then once weekly for maintenance. It's particularly effective for chronic injuries (rotator cuff tendinopathy, patellar tendinitis) that don't respond well to rest alone.

For recomposition, TB-500 enables training consistency. A lifter who can train 6 days per week without flare-ups will outperform one who trains 4 days per week and spends 2 days managing joint pain. The difference in total weekly volume compounds over months.

The Wolverine Stack combines BPC-157, TB-500, and other recovery peptides into a pre-configured protocol designed for high-intensity training phases. Stacks like this are popular during recomposition because recovery becomes the rate-limiting factor faster than strength or conditioning.

GHK-Cu (Copper Peptide) is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) that binds copper ions and modulates tissue remodeling, collagen synthesis, and anti-inflammatory signaling. GHK-Cu concentrations decline with age. From 200ng/mL at age 20 to 80ng/mL by age 60. And supplementation has been shown to improve wound healing, skin elasticity, and collagen density. Dosing is typically 1–3mg subcutaneously 2–3 times per week. For recomposition, GHK-Cu's role is connective tissue resilience: tendons and ligaments adapt more slowly than muscle, so during high-volume training phases, collagen synthesis becomes the weak link. GHK-Cu addresses that.

Epithalon is a tetrapeptide that regulates the pineal gland and may increase telomerase activity. The enzyme that maintains telomere length. Preclinical studies suggest Epithalon has anti-aging, neuroprotective, and circadian rhythm-regulating effects, though human data is limited. For recomposition, Epithalon's value is sleep quality and circadian optimization. Better sleep increases GH pulse amplitude, improves insulin sensitivity, and enhances protein synthesis overnight. Typical dosing is 5–10mg subcutaneously daily for 10–20 days, cycled 2–3 times per year.

Recovery peptides don't appear in recomposition protocols as often as GH secretagogues or fat-loss agents, but they're the reason some protocols succeed while others plateau. The limiting factor in simultaneous fat loss and muscle gain isn't always hormones. Sometimes it's simply whether you can train hard enough, consistently enough, to provide the stimulus those hormones can act on.

Best Peptides for Body Recomposition: Protocol Comparison

The table below compares the most effective peptide protocols for body recomposition based on mechanism, dosing logistics, and expected outcomes over a 12-week cycle.

Key Takeaways

• Growth hormone secretagogues like CJC-1295/Ipamorelin produce 2–3× greater GH release than either peptide alone by combining GHRH pulse amplitude with GHRP frequency.
• MK-677 elevates GH and IGF-1 for 24 hours per dose but increases appetite in 60–70% of users, making caloric control the primary challenge during recomposition phases.
• Tesamorelin selectively reduces visceral adipose tissue by 15–18% over six months without affecting subcutaneous fat, making it ideal for metabolic recomposition.
• AOD-9604 stimulates lipolysis without binding to growth hormone receptors in muscle or liver, producing fat loss with zero effect on glucose, insulin, or lean mass.
• MOTS-c activates AMPK and improves insulin sensitivity, shifting metabolism toward fat oxidation and mitochondrial biogenesis rather than direct lipolysis.
• Recovery peptides like BPC-157 and TB-500 don't directly affect body composition but enable the training volume required to sustain muscle protein synthesis during recomposition.
• Dual GLP-1/glucagon agonists like Survodutide preserve lean mass during weight loss by maintaining energy expenditure while reducing appetite. Addressing the primary limitation of GLP-1 monotherapy.

What If: Body Recomposition Peptide Scenarios

What If I'm Using a GH Secretagogue but Not Seeing Fat Loss After Six Weeks?

Increase the lipolytic stimulus by adding a metabolic modulator like AOD-9604 or MOTS-c. GH secretagogues elevate GH and IGF-1, but if you're in a caloric surplus or consuming high insulin-spiking meals around dosing windows, the anabolic signal dominates and fat oxidation is suppressed. GH stimulates lipolysis only in a low-insulin state. If insulin is elevated, hormone-sensitive lipase (the enzyme that breaks down triglycerides) is inhibited regardless of GH levels. The solution is either tighter dietary control (fasted cardio post-injection, carbohydrate timing away from GH pulses) or the addition of a peptide that bypasses insulin signaling entirely, like AOD-9604.

What If I'm Gaining Lean Mass but Also Gaining Fat on MK-677?

MK-677's appetite-stimulating effect is driven by ghrelin receptor activation in the hypothalamus and gut. If you're eating in a surplus, the GH elevation will drive anabolism, but excess calories will still be stored as fat. The fix is either stricter caloric tracking (weighing food, tracking macros) or switching to a non-appetite-stimulating GH protocol like CJC-1295/Ipamorelin. Alternatively, stack MK-677 with Tesofensine or a GLP-1 analog to offset the appetite increase. The thermogenic and satiety effects counterbalance ghrelin-driven hunger.

What If I Want to Avoid Injections Entirely — Are Oral Peptides Effective for Recomposition?

MK-677 is the only orally bioavailable GH secretagogue with clinical evidence for body composition changes. Most peptides are degraded by gastric enzymes and require subcutaneous or intramuscular injection. 5-Amino-1MQ and Tesofensine are orally active, but they're metabolic modulators rather than direct GH or IGF-1 elevators. If injections are non-negotiable, your recomposition protocol is limited to MK-677 (for anabolism) plus 5-Amino-1MQ or Tesofensine (for fat oxidation), with the understanding that results will be slower and less dramatic than injectable protocols.

What If I Have Insulin Resistance or Elevated Fasting Glucose — Which Peptides Are Safe?

AOD-9604 and MOTS-c are ideal because neither affects insulin or glucose metabolism. AOD-9604 acts exclusively on adipose tissue via beta-3 adrenergic receptors, and MOTS-c actually improves insulin sensitivity by activating AMPK and increasing glucose uptake in skeletal muscle. Avoid IGF-1 LR3 in this context. It can cause hypoglycemia in insulin-resistant individuals due to direct insulin-like effects on glucose uptake. GH secretagogues (CJC-1295, Ipamorelin, MK-677) are generally safe but should be monitored. GH is mildly insulin-antagonistic, meaning it can raise fasting glucose slightly in predisposed individuals.

The Unfiltered Truth About Peptides and Body Recomposition

Here's the honest answer: peptides accelerate body recomposition, but they don't replace the fundamentals. If your training volume isn't sufficient to stimulate hypertrophy (minimum 10–15 working sets per muscle group per week), if your protein intake is below 1.6g/kg body weight, or if you're in a steep caloric deficit (greater than 500 calories below maintenance), peptides won't produce simultaneous fat loss and muscle gain. They'll just make a bad protocol slightly less bad. The mechanism matters: GH secretagogues elevate anabolic hormones, but those hormones require substrate (amino acids) and stimulus (mechanical tension) to act on. Metabolic modulators increase fat oxidation, but if you're eating in a surplus, the oxidized fat is simply replaced by dietary fat.

The other truth: peptide recomposition works best for individuals who are already lean (men below 15% body fat, women below 25%) and trained (minimum 2–3 years of consistent resistance training). Novices and high-body-fat individuals will see better results from diet and training optimization alone. Adding peptides at that stage is spending money to marginally accelerate a process that's already happening efficiently. Peptides shine when you've exhausted the low-hanging fruit: sleep is dialed in, training is periodized, nutrition is tracked, and natural hormone optimization (zinc, magnesium, vitamin D, adequate dietary fat) is already handled. At that point, peptides move the needle. Before that point, they're expensive insurance on a foundation that isn't built yet.

Most people fail peptide recomposition protocols not because the peptides don't work, but because they expect the peptides to compensate for inconsistent training, poor sleep, or dietary chaos. They don't.

Body recomposition is hormonal recalibration, not metabolic magic. The best peptides for body recomposition create the environment. Elevated GH, improved insulin sensitivity, accelerated recovery. Where simultaneous fat loss and muscle gain become possible. But possible isn't the same as automatic. The training stimulus has to be there. The protein has to be there. The sleep has to be there. Peptides amplify what you're already doing. If what you're already doing is suboptimal, the amplification is wasted. That's the part most marketing conveniently skips, and it's the reason some researchers see dramatic results while others see expensive placebo. The compound works. The question is whether the protocol around it is worth amplifying.